Senior Management Team to Discuss Market Opportunity, Clinical and
Regulatory Progress and Commercial Plan
LAVAL, QC, Oct. 16 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that it will host a webcast presentation on Wednesday, October 24,
2007 at 10:00 am (ET) during which the Company's senior management team will
discuss the market opportunity, clinical and regulatory progress and the
commercial plan for its once-daily trazodone product.
The webcast will also include a presentation by Dr. David V. Sheehan,
Professor of Psychiatry and Director of Psychiatric Research at the University
of South Florida College of Medicine and a leading researcher and lecturer in
the areas of anxiety and mood disorders, psychopharmacology and biological
The live audio webcast will be available at www.labopharm.com. Please
connect at least 15 minutes prior to the start time to ensure adequate time
for any software download that may be required to join the webcast. The
webcast will be archived at the above web site for 30 days.
Trazodone is an atypical anti-depressant that acts as a dual serotonin
agonist and serotonin reuptake inhibitor (SARI). Trazodone appears to increase
serotonin activity via three mechanisms: the activation of neuronal serotonin
receptors; the inhibition at the neuronal serotonin feedback system which
regulates the action of serotonin; and the inhibition of the re-uptake of
serotonin. Trazodone also helps to treat depression by improving sleep as a
result of sedative effects caused by activation of histamine receptors and
initiation and restoration of deep sleep cycles as a result of serotonin
receptor activation. This may be of clinical benefit in depressed patients who
have agitation, insomnia or poor sleep quality associated with their
depression. Depression is one of the most prevalent central nervous system
disorders, affecting at least 121 million people globally. Trazodone is widely
used in its treatment with more than 14 million prescriptions written in the
U.S. alone in 2006.
About Labopharm's Once-Daily Formulation of Trazodone
Insomnia and agitation may be associated with depression. In addition to
its anti-depressive effects, trazodone has some sedative effects that can
improve sleep. Labopharm's once-daily formulation has been specifically
designed to take advantage of trazodone's unique pharmacological properties,
in addition to offering the benefits of once-daily administration and
potentially fewer side effects generally associated with peak concentrations
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company also has a
robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become a fully integrated,
international, specialty pharmaceutical company with the capability to
internally develop and commercialize its own products. For more information,
please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process and the
commercialization of the Company's products thereafter, if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: (English or French) Mark D'Souza,
Chief Financial Officer, Tel: (450) 686-0207; At The Equicom Group, Jason
Hogan, Media and Investor Relations, Tel: (416) 815-0700,
firstname.lastname@example.org; French: Eric Bouchard, Tel: (514) 844-7997,